Nephrology Dialysis Transplantation · 1989 · 78 citations · 6 references
PharmacyClinical PharmacokineticsPharmacologyDialysisHemodialysisRenal PharmacokineticsPharmacokinetics In Renal ImpairmentRenal ClearanceRenal Drug ClearanceRenal Drug DistributionRenal PharmacologyDrug Clearance By HemodialysisHemodialysis PharmacokineticsPharmacokinetics In DialysisPharmacokinetics In Kidney DiseaseRenal Blood Clearance
The pharmacokinetic profile of recombinant human erythropoietin (rHuEpo) was studied after a single intravenous dose of 150 U/kg in ten patients with various degrees of renal function: group I, creatinine clearance greater than 80 ml/min, n = 2; group II, creatinine clearance 10-50 ml/min, n = 6; group III, creatinine clearance less than 3 ml/min (patients undergoing haemodialysis) n = 2. Erythropoietin concentrations in serum and urine samples obtained over 48 h were measured by RIA. rHuEpo was cleared from circulation in an exponential fashion, the half-life ranged from 6.5 to 12.7 h (mean 9.03 h) and was not different between the groups. The apparent volume of distribution varied from 0.041 to 0.099 l/kg (mean 0.070 l/kg) this corresponds to 1.5 times the plasma volume and was unrelated to kidney function. Renal clearance (groups I, II) accounted for less than 3% of total body clearance, both parameters were unaffected by decreasing renal function. These results indicate that, in accordance with animal data, the elimination of rHuEpo occurs mainly through non-renal mechanisms.
6
Pharmacokinetics of erythropoietin in intact and anephric dogs.
J S Fu, Juan J.L. Lertora, J. Brookins et al. · PubMed · 1988 · 37 citations